Late Breaking Abstract Presented at the Japanese Urological Association Annual Meeting on Aquablation Therapy Outcomes for Men in Japan with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia
April 29 2024 - 8:00AM
PROCEPT BioRobotics® Corporation (Nasdaq: PRCT) (the “Company”), a
surgical robotics company focused on advancing patient care by
developing transformative solutions in urology, today announced the
presentation of a late breaking post-market survey at the Japanese
Urological Association (JUA) Annual Meeting on positive Aquablation
therapy outcomes for men in Japan with lower urinary tract symptoms
(LUTS) due to benign prostatic hyperplasia (BPH).
“The data presented at the JUA showcase the global reach of
Aquablation therapy and its safety and effectiveness in treating
men across geographic regions and demographics,” said Reza Zadno,
CEO of PROCEPT BioRobotics. “The reproducible results observed in
numerous real-world Aquablation therapy cases continue to support a
paradigm shift in the surgical treatment of BPH.”
Data Highlights
- 103 men were treated with a mean age
and baseline international prostate symptom score (IPSS) of 71 ± 7
and 18 ± 9, respectively
- Mean prostate volume was 82 ml
(range 33-242 ml)
- Proportion of patients who were on
BPH medication, had prior BPH surgery or catheter use for retention
were 58%, 1% and 26%, respectively
- No reports of pad-use incontinence
or serious device-related adverse events
- Three-month average IPSS improved to
7 ± 5
- Quality-of-life baseline score was 5
± 1 and at three-month follow-up, improved to 2 ± 2
“It was an honor to deliver the late breaking presentation that
treated only Japanese men with LUTS due to BPH,” said Dr. Nobuyuki
Hinata, Professor and Chairman of Hiroshima University Hospital.
“The results showed the contemporary Aquablation procedural safety
in Japanese men is exceptional in a broad range of prostate sizes
along with significant symptom reduction. This data align with the
numerous global publications and real-world data that have eclipsed
50,000 procedures.”
For more information on Aquablation therapy, please visit
www.procept-biorobotics.com or www.procept-biorobotics.jp.
About Aquablation TherapyAquablation therapy is
the first and only ultrasound guided, robotic-assisted, heat-free
waterjet for the treatment of BPH. The system’s real-time
ultrasound imaging provides the surgeon with a multi-dimensional
view of the prostate enabling personalized treatment planning
tailored to each patient’s unique anatomy. The surgeon can specify
which areas of the prostate to remove while preserving the anatomy
that controls erectile function, ejaculatory function, and
continence. Once the treatment plan is mapped by the surgeon, the
predictable robotic-assisted execution enables prostate tissue to
be removed in a precise, targeted, and controlled fashion.
About PROCEPT BioRobotics CorporationPROCEPT
BioRobotics is a surgical robotics company focused on advancing
patient care by developing transformative solutions in urology.
PROCEPT BioRobotics develops, manufactures and sells the AquaBeam
Robotic System, an advanced, image-guided, surgical robotic system
for use in minimally invasive urologic surgery with an initial
focus on treating benign prostatic hyperplasia, or BPH. BPH is the
most common prostate disease and impacts approximately 40 million
men in the United States. PROCEPT BioRobotics designed Aquablation
therapy to deliver effective, safe and durable outcomes for males
suffering from lower urinary tract symptoms, or LUTS, due to BPH
that are independent of prostate size and shape or surgeon
experience. The Company has developed a significant and growing
body of clinical evidence, which includes over 150 peer-reviewed
publications, supporting the benefits and clinical advantages of
Aquablation therapy.
Forward-Looking StatementsThis release contains
forward-looking statements within the meaning of federal securities
laws, including with respect to the Company’s projected financial
performance for full year 2024, statements regarding the potential
utilities, values, benefits and advantages of Aquablation® therapy
performed using PROCEPT BioRobotics’ products, including AquaBeam®
Robotic System, which involve risks and uncertainties that could
cause the actual results to differ materially from the anticipated
results and expectations expressed in these forward-looking
statements. You are cautioned not to place undue reliance on these
forward-looking statements. Forward-looking statements are only
predictions based on our current expectations, estimates, and
assumptions, valid only as of the date they are made, and subject
to risks and uncertainties, some of which we are not currently
aware. Forward-looking statements may include statements regarding
financial guidance, market opportunity and penetration, the
Company’s possible or assumed future results of operations,
including descriptions of the Company’s revenues, gross margin,
profitability, operating expenses, installed base growth,
commercial momentum, reimbursement coverage, overall business
strategy, or information regarding the impact of other global
events on the Company and its operations. Forward-looking
statements should not be read as a guarantee of future performance
or results and may not necessarily be accurate indications of the
times at, or by, which such performance or results will be
achieved. These forward-looking statements are based on the
Company’s current expectations and inherently involve significant
risks and uncertainties. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of these risks and
uncertainties. These risks and uncertainties are described more
fully in the section titled “Risk Factors” in the Company’s filings
with the Securities and Exchange Commission (the “SEC”), including
the Company’s annual report on Form 10-K expected to be filed with
the SEC on or about February 28, 2024. PROCEPT BioRobotics does not
undertake any obligation to update forward-looking statements and
expressly disclaims any obligation or undertaking to release
publicly any updates or revisions to any forward-looking statements
contained herein. These forward-looking statements should not be
relied upon as representing PROCEPT BioRobotics’ views as of any
date subsequent to the date of this press release.
Important Safety InformationAll surgical
treatments have inherent and associated side effects. For a list of
potential side effects visit
https://aquablation.com/safety-information/Media
Contact:Lauren CohenSenior Director, Integrated Marketing
Communicationsl.cohen@procept-biorobotics.com
Investor Contact: Matt BacsoVP, Investor
Relations and Business
Operationsm.bacso@procept-biorobotics.com
PROCEPT BioRobotics (NASDAQ:PRCT)
Historical Stock Chart
From Apr 2024 to May 2024
PROCEPT BioRobotics (NASDAQ:PRCT)
Historical Stock Chart
From May 2023 to May 2024